Regarding the future clinical development of olmutinib, the phase II ELUXA 1 study (ClinicalTrials.gov, NCT02485652) is recruiting patients with advanced EGFRT790M-positive NSCLC after prior EGFR-TKI therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.